Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib by Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen

Get full text

Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors by Erick Velasquez, Nastya Kassir, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Steve Dang, Dale Miles, James Lu

Get full text

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics by Kit Wun Kathy Cheung, Yang Tang, Doreen Anders, Teresa Barata, Astrid Scalori, Priya Agarwal, Rucha Sane, Sravanthi Cheeti

Get full text

Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations by Julia Suchomel, Priya Agarwal, Doreen Anders, Kevin Hughes, Yang Tang, Rucha Sane, Astrid Scalori, Sunil Sharma, Sravanthi Cheeti

Get full text

A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS by Jonathan S. Katz, Jeffrey D. Rothstein, Merit E. Cudkowicz, Angela Genge, Björn Oskarsson, Avis B. Hains, Chen Chen, Joshua Galanter, Braydon L. Burgess, William Cho, Geoffrey A. Kerchner, Felix L. Yeh, Arundhati Sengupta Ghosh, Sravanthi Cheeti, Logan Brooks, Lee Honigberg, Jessica A. Couch, Michael E. Rothenberg, Flavia Brunstein, Khema R. Sharma, Leonard van denBerg, James D. Berry, Jonathan D. Glass

Get full text